TDP-43 Proteinopathy in ALS

Introduction

Tdp 43 Proteinopathy In Als represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

TDP-43 (TAR DNA-binding protein 43) is a nuclear RNA/DNA-binding protein that is central to the pathogenesis of most cases of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Pathological TDP-43 aggregation is found in approximately 95% of ALS cases and 50% of FTD cases, making it a key therapeutic target. ^{1(2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis2006}

Pathway Diagram

Molecular Mechanisms

1. TDP-43 Normal Function

TDP-43 is a heterogeneous nuclear ribonucleoprotein (hnRNP) with essential functions: ^{2(2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis2008}

• DNA binding: Binds to TAR DNA sequences (TG-rich)

• RNA splicing: Regulates alternative splicing of thousands of transcripts

• RNA stability: Controls mRNA turnover and transport

• Stress response: Forms stress granules under cellular stress

Normal localization: Predominantly nuclear, with some cytoplasmic localization for transport. ^{3'(2010) ALS associated with TDP-43: a new role for an old protein'2010}

2. Pathological Mislocalization

In disease, TDP-43 undergoes characteristic changes: ^{4(2009) TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity2009}

• Nuclear depletion: Loss of nuclear TDP-43

• Cytoplasmic aggregation: Formation of stress granules and inclusions

• Phosphorylation: Hyperphosphorylation at Ser409/410

• Ubiquitination: Post-translational modification

• C-terminal fragmentation: Generation of toxic fragments

3. Loss of Nuclear Function

Nuclear TDP-43 loss disrupts: ^{5(2005) Nuclear factor TDP-43 can affect selected gene expression via splicing inhibition2005}

Splicing dysregulation: ^{6'(2011) TDP-43 in central nervous system development and function: clues to TDP-43-associated neurodegeneration'2011}

• Cryptic exon inclusion

• Exon skipping

• Inappropriate splicing of:

  • Neuronal development genes

  • Synaptic function genes

  • Mitochondrial function genes

RNA processing defects: ^{7(2012) The genetics and neuropathology of amyotrophic lateral sclerosis2012}

• Impaired mRNA transport

• Reduced translation

• Altered RNA stability

4. Gain of Cytoplasmic Toxicity

Cytoplasmic TDP-43 aggregates cause: ^{8(2017) TDP-43 pathology in Alzheimer's disease2017}

Stress granule dysfunction: ^{9(2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia2011}

• Sequestration of translation machinery

• Impaired stress response

• Persistence of stress granules

Mitochondrial dysfunction: ^{10'(2019) Global epidemiology of ALS: a systematic review of the literature'2019}

• Direct binding to mitochondria

• Impaired mitochondrial trafficking

• Reduced ATP production

Nuclear pore pathology: ^{2(2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis2008}0

• Nuclear export dysregulation

• Nucleocytoplasmic transport defects

Genetic Causes

ALS-Causing Mutations

| Gene | Mutation Effect | % of ALS | ^{2(2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis2008}1 |------|---------------|----------| ^{2(2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis2008}2 | TARDBP | Autosomal dominant | ~3-5% | ^{2(2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis2008}3 | FUS | Autosomal dominant | ~3-5% | | C9orf72 | Hexanucleotide repeat | ~40% | | TIA1 | Stress granule regulation | ~1% |

Mutations Affecting TDP-43

• TARDBP: Direct mutations in TDP-43 coding region

• FUS: FUS protein sequesters TDP-43

• C9orf72: RNA foci sequester TDP-43

• TIA1: Stress granule dynamics altered

• OPTN: Autophagy impairment affects clearance

Disease Associations

Amyotrophic Lateral Sclerosis (ALS)

• 95% of ALS cases have TDP-43 pathology

• All sporadic ALS cases

• All non-SOD1 familial ALS

• Includes C9orf72, FUS, TARDBP mutations

Frontotemporal Dementia (FTD)

• 50% of FTD cases have TDP-43 pathology

• FTLD-TDP subtype

• Behavioral variant FTD (bvFTD)

• Primary progressive aphasia (PPA)

ALS-FTD Spectrum

• Overlapping clinical features

• Shared pathology (TDP-43)

• Common genetic causes (C9orf72)

• ~15% of patients develop both

Therapeutic Implications

Strategies Under Development

1. TDP-43 aggregation inhibitors

   • Small molecules targeting protein-protein interactions

   • Compounds promoting clearance

2. RNA-targeted therapies

   • Antisense oligonucleotides for TARDBP mutations

   • Splicing modulators

3. Stress granule modulators

   • Inhibitors of stress granule formation

   • Compounds promoting dissolution

4. Mitochondrial protectors

   • Antioxidants

   • Mitochondrial biogenesis inducers

5. Autophagy enhancers

   • TFEB activators

   • Autophagy-inducing compounds

Biomarkers

• CSF TDP-43: Diagnostic potential

• Phospho-TDP-43: Disease-specific

• Neurofilaments: Disease progression

• PET tracers: In development

Cross-Links

• ALS Overview

• C9orf72 ALS Pathway

• SOD1 ALS Pathway

• FTD-TDP43 Pathway

• Stress Granules

• Mitochondrial Dysfunction

Background

The study of Tdp 43 Proteinopathy In Als has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• Alzheimer’s Disease

• Amyloid Hypothesis

• Tau Pathology

• Parkinson’s Disease

• Alpha-Synuclein Pathway

External Links

• PubMed - Biomedical literature

• Alzheimer’s Disease Neuroimaging Initiative - Research data

• Allen Brain Atlas - Brain gene expression data

Confidence Assessment

🟡 Moderate Confidence

Dimension	Score
Supporting Studies	15 references
Replication	0%
Effect Sizes	25%
Contradicting Evidence	0%
Mechanistic Completeness	75%

Overall Confidence: 45%

---

Recent Research Updates (2024-2026)

• Hruska-Plochan M et al., Nature (2024 Feb)

• Eisen A et al., Prog Neurobiol (2024 Mar)

• Keeley O et al., Acta Neuropathol Commun (2024 Dec 21)

• Zamani A et al., Neurobiol Dis (2025 Mar)

• Dubey SK et al., Neuron (2026 Mar 4)

Additional Reading

TDP-43 Aggregation Mechanisms

Structural Basis of Aggregation

TDP-43 contains multiple domains that contribute to its aggregation propensity:

• N-terminal domain (1-414): Contains the nuclear localization signal (NLS) and the RNA recognition motif (RRM1)

• RRM1 (104-262): Binds to UG-rich RNA sequences

• RRM2 (262-350): Additional RNA-binding capacity

• Low-complexity domain (LCD, 341-414): Intrinsically disordered region critical for phase separation and aggregation

Post-Translational Modifications

Pathological TDP-43 is characterized by specific PTMs:

Modification	Site	Significance
Phosphorylation	Ser409/Ser410	Disease-specific, drives aggregation
Phosphorylation	Ser379/Ser403/Ser409	Multiple sites in patient tissue
Ubiquitination	Lys residues	Marks for proteasomal degradation
Sumoylation	Lys residues	May promote aggregation
C-terminal truncation	Various sites	Generates toxic fragments

Aggregation Kinetics

• Primary nucleation: Spontaneous assembly of TDP-43 monomers

• Secondary nucleation: Seeding by existing aggregates

• Surface-catalyzed nucleation: Growth on foreign surfaces

• Oligomer formation: Toxic intermediate species

• Fibril elongation: Formation of inclusions

TDP-43 in RNA Metabolism

Essential RNA Targets

TDP-43 regulates splicing and stability of critical neuronal transcripts:

Function	Key Targets	Disease Relevance
Neuronal development	UNC13A, STX3, PRKN	Developmental defects
Synaptic function	SYN1, DLGL1, CACNA2D3	Synaptic dysfunction
Mitochondrial function	NDUFA2, ATP5F1B	Energy deficits
Axonal transport	DYNC1H1, KIF5C	Axonal pathology
RNA splicing	Cryptic exons in multiple genes	Global splicing disruption

Cryptic Exon Inclusion

One of the most significant consequences of TDP-43 loss:

• UNC13A cryptic exons: Inclusion creates truncated non-functional protein

• Other targets: SEMA3B, SEL1L, RIMBP2

• Functional consequences: Loss of essential neuronal proteins

• Therapeutic opportunity: Antisense oligonucleotides can block cryptic exons

TDP-43 in Other Neurodegenerative Diseases

Alzheimer’s Disease

• TDP-43 pathology found in ~20-30% of AD cases

• Often coexists with tau and amyloid pathology

• Associated with greater cognitive impairment

• May represent a distinct disease subtype

Parkinson’s Disease

• TDP-43 in ~10-15% of PD cases

• Associated with rapid disease progression

• More common in certain genetic forms (LRRK2, GBA)

Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE)

• TDP-43 pathology in aging brain

• Clinically resembles Alzheimer’s disease

• Affects limbic structures preferentially

• High prevalence in individuals over 80

Experimental Models

In Vitro Models

• Purified protein aggregation: Recombinant TDP-43 LCD forms fibrils

• Cell lines: Transient transfection of mutant TDP-43

• iPSC-derived neurons: Patient-derived motor neurons

• Organoids: Brain organoids with TDP-43 pathology

In Vivo Models

• TARDBP transgenic mice: Wild-type and mutant TDP-43

• Conditional models: Inducible TDP-43 expression

• Knock-in models: Endogenous TDP-43 mutations

• Viral-mediated expression: AAV-delivered TDP-43

Therapeutic Strategies

RNA-Targeted Approaches

Approach	Mechanism	Stage
ASOs for TARDBP	Reduce mutant TDP-43	Preclinical
Splicing modulators	Prevent cryptic exon inclusion	Preclinical
RNA stabilizers	Enhance nuclear TDP-43 function	Preclinical

Protein-Targeted Approaches

Approach	Mechanism	Stage
Aggregation inhibitors	Block protein-protein interactions	Preclinical
Small molecule stabilizers	Prevent misfolding	Preclinical
Antibody therapies	Anti-TDP-43 antibodies	Preclinical

Enhancing Clearance

Approach	Mechanism	Stage
Autophagy enhancers	TFEB activators	Preclinical
Proteasome enhancers	Increase degradation	Preclinical
Immunotherapies	Antibody-mediated clearance	Preclinical

Biomarker Development

Diagnostic Biomarkers

• Phospho-TDP-43 in CSF: Highly specific for TDP-43 proteinopathy

• Total TDP-43 in CSF: Elevated in disease

• NfL in blood/CSF: General neurodegeneration marker

Prognostic Biomarkers

• Disease progression: Rate of NfL change

• Therapeutic response: Changes in TDP-43 species

• Phenotype prediction: TDP-43 pathology pattern

Monitoring Biomarkers

• PET tracers: In development for TDP-43

• Peripheral markers: Blood cells, skin fibroblasts

• Neuroimaging: TDP-43-related structural changes